Canadian health committee proposes National Pharmacare programme

INICIO/Políticas y legislación | Posted 04/05/2018 post-comment0 Post your comment

On 19 April 2018, Canada’s Standing Committee on Health released Pharmacare Now: Prescription Medicine Coverage for All Canadians, a report advocating the establishment of a national pharmacare programme, i.e. a publicly funded prescription drug coverage programme for all Canadians.

81 MD002388

The report is the result of two years of hearings that included 99 witnesses.

Canadians do not currently have access to a single system of public insurance coverage for prescription drugs. They are instead covered by a patchwork of public and private drug plans, while a minority pay completely out of pocket for their prescriptions. This ‘dysfunctional’ system has been blamed for contributing to Canadians paying some of the highest prices for prescription drugs in the world [1] and to an estimated one in five Canadians not taking their prescription drugs because of cost considerations.

According to the report, the main purpose of a national pharmacare programme would be to ensure that ‘no Canadian faces financial barriers in accessing medically necessary prescription drugs’.

The report makes 18 recommendations included under four main action areas:

  1. Expanding the Canada Health Act to include prescription drugs dispensed outside hospitals, with costs to be shared by the federal, provincial and territorial governments
  2. Development of a common voluntary national prescription drug formulary
  3. Improving drug pricing and reimbursement processes
  4. Improving data and information systems

The committee believes that these ‘concrete’ recommendations ‘will lay the framework for the provision of pharmacare to all Canadians’.

Governmental plans are cheaper to run than private drug plans, because governments negotiate low prices with drug companies and they do not cover as many drugs, research has shown. Canada’s Parliamentary Budget Officer has estimated that CA$4.2 billion annually would be saved on prescriptions if Canadians were covered by these cheaper provincial drug plans.

Related articles
Canada’s generics industry to cut prices by up to 40%

Quebec hopes to save millions by tendering for generics

1.  GaBI Online - Generics and Biosimilars Initiative. Generics still cost more in Canada, but prices decreasing []. Mol, Belgium: Pro Pharma Communications International; [cited 2018 May 4]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: Canadian Government, CBC

comment icon Comments (0)
Post your comment
Related content
FDA publishes final Q&A on biosimilar development and the BPCI Act
INICIO/Políticas y legislación Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
INICIO/Políticas y legislación Posted 08/10/2021
USA BIOSIM Act introduction
02 AA010638
INICIO/Políticas y legislación Posted 17/09/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010